Editor's Choice Main Category: Stroke Also Included In: Neurology / Neuroscience Article Date: 15 Apr 2013 - 11:00 PDT
Current ratings for: Acorda's MS Drug Ampyra Helps Stroke Patients Walk
5 (1 votes)
In a proof-of- concept Phase II study, Ampyra (dalfampridine extended release 10mg tablets) significantly improved walking in patients with post-stroke deficits. Post-stroke deficits include impaired walking, motor and sensory function, as well as manual dexterity - collectively known as chronic neurological deficits. These deficits often persist in stroke victims.
Ron Cohen, M.D., President and Chief Executive Officer, Acorda Therapeutic Incorporated, said:
We are analyzing the data further to better understand the entirety of the results. After we complete the analysis, we plan to discuss the development program with the FDA. There are more than seven million stroke survivors in the United States, and approximately half of them have some lasting mobility impairment. There are no medications currently available for these patients, so new therapies are desperately needed."
The trial involved 83 people who had had an ischemic stroke at least six months before enrollment. They all had chronic motor deficits.
The participants received dalfampridine-ER 10 mg for 14 days and then placebo for 14 days, or vice-versa.
The study's primary outcomes were to examine the medication's tolerability and safety, as well as exploring various measures of efficacy (effectiveness).
The following adverse events were reported in this study:
See the original post:
Acorda's MS Drug Ampyra Helps Stroke Patients Walk